Shares of Halozyme Therapeutics (HALO -12%) plunge after Jefferies cuts its rating to Hold from...

|About: Halozyme Therapeutics, Inc. (HALO)|By:, SA News Editor

Shares of Halozyme Therapeutics (HALO -12%) plunge after Jefferies cuts its rating to Hold from Buy, noting likely market challenges for three products to be launched by the biopharma company's partners. HALO's royalty revenue is unlikely to drive further appreciation for the stock, the firm adds.